1999
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Research 1999, 59: 1015-20. PMID: 10070957.Peer-Reviewed Original ResearchConceptsHealth Study cohortBreast cancer riskBreast cancerHormone levelsA2 alleleCancer riskNurses' Health Study cohortStrong independent risk factorA2/A2 genotypeCYP17 A2 alleleElevated levelsAdvanced breast cancerIncident breast cancerIndependent risk factorPolycystic ovarian syndromeCertain steroid hormonesA1/A1 genotypeCase-control studyPlasma hormone levelsSteroid hormone levelsLater agePremenopausal womenCYP17 genotypeHormone replacementOvarian syndrome
1997
Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases.
Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, Manson JE, Garland M, Stampfer MJ, Willett WC, Speizer FE, Hunter DJ. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 511-5. PMID: 9232338.Peer-Reviewed Original ResearchConceptsBreast cancerGene deletion polymorphismCase seriesDeletion polymorphismHealth StudyNull genotypeGSTM1 deletionGlutathione S-transferase class muPrevalent breast cancerIncident breast cancerNurses' Health StudyGSTM1 gene deletion polymorphismBreast cancer riskDuration of survivalAge-matched controlsGSTM1 null genotypeBreast cancer prognosisMolecular epidemiologic studiesImproved survivalCigarette smokingIncident casesOdds ratioPrevalent casesEpidemiologic studiesCancer risk